Parkinson disease is believed to have a prodromal phase, long before neuronal death occurs, and some studies have focused on the gut-brain axis to look for clues.
Irritable bowel syndrome (IBS) could be an early warning sign of Parkinson disease (PD), according to a recent systematic review and meta-analysis examining potential links.
Gastrointestinal symptoms are the most common nonmotor symptoms in a majority of patients PD, and researchers are exploring some of the underlying pathological mechanisms and risk factors that both PD and IBS share. PD is believed to have a prodromal phase, long before neuronal death occurs, and some studies have focused on the gut-brain axis to look for clues.
In this study, researchers searched 2 databases up until August 2021 for research that fulfilled 4 points:
Case reports, animal studies, and reviews were excluded.
From 192 articles, 6 were ultimately chosen for analysis, involving 58,645 patients with PD. Risk estimates from the individual studies were pooled using random-effects models.
Results showed the overall risk for PD in patients who had IBS patients was significantly higher than the general population (odds ratio [OR], 1.5; 95% CI, 1.29–1.75; P < .001).
However, older patients with IBS (≥65 years) appeared to have higher risk (OR, 1.44; 95% CI, 1.3–1.59; P < .001) compared with patients aged 40 to 64 years (OR, 1.32, 95% CI, 1.05–1.64; P = .017).
Subgroup analysis revealed no significant differences in risk between men (OR, 1.47, 95% CI, 1.3–1.67; P < .001) and women (OR, 1.51, 95% CI, 1.29–1.75; P < .001).
The authors said exactly how IBS may increase the risk for PD is not fully known, but several pathways may be involved, including the microbiota-brain-gut axis. In a murine model of PD, dysbiosis of the gut microbiota was needed before the development of neuroinflammation and α-synuclein-mediated motor deficits; in addition, human gut microbiome alterations have been noted in other studies.
The authors said the low-grade intestinal inflammation of IBS may assist the development of PD, as the levels of inflammatory markers in PD are significantly higher than in healthy controls and correlate with the level of intestinal neuronal α-synuclein.
IBS may appear decades before PD’s hallmark motor symptoms appear. Two of the studies included in this review found that the risk of PD was highest during the 2 years of follow-up after diagnosis of IBS.
The authors said their review had the usual limitations common to meta-analyses, such as the small number of included studies and the observational, retrospective nature. The possibility of confounders exists, such as family history or lifestyle influences.
However, the review also had several strengths, including the fact that "the level of heterogeneity for the analyses was low, making the pooled results more convincing."
Reference
Lu S, Jiang HY, Shi YD. Association between irritable bowel syndrome and Parkinson's disease: a systematic review and meta-analysis. Acta Neurol Scand. Published online December15, 2021. doi:10.1111/ane.13570
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
November 20th 2024Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
November 19th 2024The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Read More